Showing 11-20 of 48 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Mesh Oxygen Transporter for improved engraftment of human stem cell-derived pancreatic islet cells in the subcutaneous site | The Regents of the University of California, San Francisco | Hirotake Komatsu | Cures | 01-March-2024 to 31-July-2025 | $294,796.07 |
| Sequential multi-molecule release from nanofiber scaffolds for improved stem cell-derived islet transplantation under the skin | The Regents of the University of California, San Francisco | Hirotake Komatsu | Cures | 01-March-2024 to 31-July-2026 | $845,444.86 |
| Generation of vascularized, transplantable islets from human iPSC-derived beta and isogenic vasculogenic cells | The Regents of the University of California, San Francisco | Julie Sneddon | Cures | 01-July-2024 to 30-June-2026 | $600,000.00 |
| Gaining insight into type 1 diabetes pathogenesis through STAT gain of function | The Regents of the University of California, San Francisco | Martin Thelin | Cures | 01-March-2024 to 28-February-2025 | $110,000.00 |
| Designing a safe and effective strategy for T1D cell replacement therapy | The Regents of the University of California, San Francisco | Nur Shabrina Amirruddin | Cures | 01-March-2025 to 29-February-2028 | $264,895.00 |
| Mechanisms of parathyroid protection of transplanted islets | The Regents of the University of California, San Francisco | Peng Xiao | Cures | 01-March-2024 to 28-February-2027 | $228,995.00 |
| Armored SC-beta | The Regents of the University of California, San Francisco | Qizhi Tang | Cures | 01-December-2023 to 30-November-2025 | $499,999.25 |
| Northern California Breakthrough T1D Center of Excellence | The Regents of the University of California, San Francisco | Qizhi Tang | Cures | 01-October-2024 to 30-September-2028 | $6,000,000.00 |
| Identifying regulators of primary human beta cell survival and proliferation | The Regents of the University of California, San Francisco | Rebecca Lee | Cures | 01-March-2024 to 28-February-2027 | $235,025.00 |
| Allogeneic hypoimmunogenic Pancreatic Islets for Treatment of Diabetes in the Intra-Muscular Site | The Regents of the University of California, San Francisco | Tobias Deuse | Cures | 01-August-2024 to 31-July-2026 | $799,998.40 |